Skip to main content
Premium Trial:

Request an Annual Quote

Horizon Licenses Stanford IP for AAV Serotype

NEW YORK (GenomeWeb) – Horizon Discovery today announced a non-exclusive deal to license intellectual property from Stanford University related to the use of a proprietary serotype of adeno-associated virus for commercial applications involving homologous recombination in gene editing.

The technology was developed by Mark Kay at the Stanford School of Medicine and is an artificial serotype of AAV. Known as AAV-DJ, it transduces a broader range of mammalian cells than any naturally occurring AAV serotype, which will allow Horizon to target an increased range of cell types, the Cambridge, UK-based firm said. In combination with the firm's existing license to use recombinant AAV from the University of Washington, Horizon is the only source of this mechanism for gene editing, it added.

Earlier this year, Horizon launched its Genassist range of gene editing kits and reagents that enable "easier, robust implementation" of both rAAV and CRISPR gene editing experiments.

Financial and other terms of the deal were not disclosed.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.